Pediatrics List Organized by Indication

DRUGS

LABELED INDICATION

PEDIATRIC SUBSECTION

PEDIATRIC DOSING

Diazoxide

  • Short term BP reduction for severe, non-malignant and malignant hypertension

None

None

Digoxin Injectable

  • Heart Failure
  • Atrial Fibrillation

Labeled S&E for Heart Failure in premature infants, infants and children only

  • Heart Failure:

Digitalizing and

Maintence

Recommenda-

Tions

For premature

Babies to

Children

Dopamine

  • Correction of hemodynamic imbalances in shock after MI, traum, endotoxic septicemia, surgery and renal failure
  • Correction of imbalances in conditions of chronic refractory cardiac decompensation

S&E not established

None

Dobutamine

  • Short-term inotropic support
  • Trials not >48hrs of use

No S&E studies

None

Nitroprusside

  • Immediate Reduction of BP in hypertensive crises
  • Producing controlled hypotension in order to reduce bleeding
  • Acute congestive heart failure

None

None

 

Lorazapam Injectable

  • Status Epilepticus
  • Preanesthetic
  • Status Epilepticus No safety studies in children
  • Preanesthetic No efficacy in children
  • None

    Lorazepam Capsules

    • Anxiety disorders
    • Short-term relief of anxiety
    • Anxiety assít with depressive Symptoms

    S&E not <12years

    None

    Amphetamine/Dextroamphetamine tablets/capsules

    Attention Deficit Disorder with Hyperactivity

    Long Term Effects NOT studies

     

    Valproate Injectable

    • In place of oral administration
    • Monotherapy and adjunctive therapy tx Complex partial seizures
    • Simple and complex absence seizure
    • Multiple seizure types inc absence seizure
  • No S&E in Children
  •  

    Dosage only Complex Partial Seizures : For adults and children 10 years of age or older.

    Bupropion

    Depression

    <18 has not been established

    Studied in 104 children age 6-16

    Promethazine

    • Ameliorate allergic reaction to blood or plasma
    • In Anaphylaxis as adjunct to epinephrine and other standard measures
    • Uncomplicated allergic condition in place oral therapy
    • Sedation/relief apprehension
    • Active tx of motion sickness
    • Prevention and control N/V with anesthesia and surgery
    • Adjunct to analgesics for control postop pain
    • Preop, postop, and obstetric sedation
    • IV in special surgical situation

    S&E in <2years not established

    the dosage should not exceed half that of the suggested adult dose. As an adjunct to premedication, the suggested dose is 0.5 mg per lb. of body weight

    Metaproterenol

    Bronchodilator for bronchial asthma and reversible bronchospasm

    No S&E <6years for inhalation solution and <12years for inhalation

    >12years 2-3 inhalations q 3-4hrs

    Terbutaline Ampules

    Prevention and reversal of bronchospasm

    >=12years

    None

    Acyclovir Suspension, Capsules, Tablets

    • Herpes Zoster
    • Genital Herpes
    • Chickenpox

    No S&E <2yrs

    2 trials, 20 mg/kg 4 times daily (up to 3200 mg per day) for 5 days

    3rd trial, doses of 10, 15, or 20 mg/kg were administered 4 times daily for 5 to 7 days

    Acyclovir

    Ointment

    • Initial herpes genitalis
    • limited nonlife-threatening mucocutaneous Herpes simplex virus in immuno-compromised

    None

    None

    Ampicillin

    • Respiratory Tract Infections caused by S. pneumoniae, Staph. Aureus, H. Influ., and Group A beta-hemolytic streptococci
    • Bacterial Meningitis caused by E. coli, Group B. Streptococci and other Gram-negative bacteria (Listeria monocytoenes, N. meningitidis)
    • Septicemia and Endocardititis caused by susceptible Gram-positive organisms indluding Streptococcus sp., penicillin G-suspeptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella. Endocarditis due to enterococcal strains
    • UTI caused by sensitive strains of E. coli and Proteus mirabilis
    • GI Infections caused by Salmonella typhosa, other Salmonella sp., and Shigella sp.
  • Resp Tract and Soft Tissues:
  • >1month

    • GI/GU

    Children and Adults

    • Bacterial

    Meningitis

    Children and

    Adults

    • Resp Trat and Soft Tissues:

    <40kg: 25-50 mg/kg/day div q6-8hrs

    • GI/GU

    <40kg: 50mg/kg/day div q6-8hrs

    >40kg:

    500mg q6-8hrs

    • Bacterial Meningitis children and adults:

    150-

    200mg/kg/day

    • Septicemia

    Children and adults: 150-200 mg/kg/day

    Metronidazole

    • Gram- positive anaerobes: Clostridum, Eubacterium, Peptococcus niger, Pepto-streptococcus
    • Gram-neg anaerobes: Bacteroides frag group, Fusobacterium species, Prevotella speciies, Porphyromonas speciies
    • Protozoal parasites: Entamoeba histolytica, Trichomonas vaginalis

    None established

    None

    Azithromycin

    • Community-acquired pneumonia due to Chlamydia pneumoniae, Haemophilus influenzae, Legionella, Moraxella catarrhalis, Mycoplasma pneumoniae, Staphylococcus aureus, or Streptococcus pneumoniae in patients who require initial intravenous therapy.
    • Pelvic inflammatory disease due to Chlamydia trachomatis, Neisseria gonorrhoeae, or Mycoplasma
  • AOM: no S&E<6mo
  • Community Acquired Pneumonia: no S&E<6mo
  • Pharyngitis/Tonsillitis: no S&E<2 years
  • AOM: 30mg/kg
  • Community Acquired Pneumonia: 10mg/kg d1-> 5mg/kg d2-5
  • Pharyngitis/Tonsillitis: 12mg/kg d1-5

    Cimetidine

    • Short term tx active duodenal ulcer
    • Maintenance therapy for duodenal ulcer
    • Short-term tx of active benign gastric ulcer
    • Erosive GERD
    • Prevention UGI bleeding in critically ill patients
    • Tx pathological hypersecretion

    Not recommended children <16years

    Limited Clinical Experience doses 20-40mg/kg/day

    Metoclopramide

    • Symptomatic GE Reflux
    • Diabetic Gastroparesis
    • Prevention N/V assít w/chemo
    • Prevention post-op N/V
    • Small Bowel intubation
    • Radiologic Exam

    No S&E in children

    Except in small bowel intubation

    The recommended single dose is: Pediatric patients above 14 years of age and adults--10 mg metoclopramide base. Pediatric patients (6-14 years of age)--2.5 to 5 mg metoclopramide base; (under 6 years of age)--0.1 mg/kg metoclopramide b

    Auralgan

    In AOM:

    • pair and inflammation reduction in congestive and serious stages
    • adjuvant therapy w/systemic antibiotics

    None

    None

    S&E = Safety and Efficacy

    Compiled by Susannah Olnes, Medical Officer, OPDDPI, Pediatrics Team